Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) had its price target boosted by equities researchers at Oppenheimer Holdings, Inc. from $4.00 to $7.00 in a report issued on Thursday. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price objective suggests a potential upside of 131.02% from the stock’s current price.

Several other equities research analysts have also issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a research note on Wednesday, June 21st. HC Wainwright lifted their price target on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, Citigroup Inc. reaffirmed a “hold” rating and set a $1.50 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, September 29th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.10.

Catabasis Pharmaceuticals (NASDAQ:CATB) opened at 3.03 on Thursday. Catabasis Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $5.74. The company’s market capitalization is $68.12 million. The firm has a 50-day moving average price of $1.93 and a 200 day moving average price of $1.93.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. On average, analysts predict that Catabasis Pharmaceuticals will post ($1.39) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Oppenheimer Holdings, Inc. Raises Catabasis Pharmaceuticals, Inc. (CATB) Price Target to $7.00” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at

A number of hedge funds have recently modified their holdings of the business. Virtu KCG Holdings LLC bought a new stake in Catabasis Pharmaceuticals during the second quarter worth about $271,000. Oppenheimer & Co. Inc. lifted its stake in Catabasis Pharmaceuticals by 33.3% during the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Catabasis Pharmaceuticals during the first quarter worth about $106,000. 32.90% of the stock is owned by hedge funds and other institutional investors.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.